sapanisertib also known experimental small molecule inhibitor mtor administered orally targets developed millennium phase ii clinical trials breast cancer endometrial cancer glioblastoma renal cell carcinoma thyroid drug well tolerated patients advanced solid tumours phase httpsenwikipediaorgwikisapanisertib